

## Actively recruiting M. Blostein JGH Thrombosis Program Studies (Jan 2013)

Name of study/ Protocol number	Study Description	Type of patients potentially eligible	Time window for recruitment	Site PI MD	Coordinator	Contact for Research Ethics Office
<b>BRIDGE STUDY</b> <u>11-128</u>	RCT of placebo vs enoxaparin for pre-operative and post-operative bridging	Patients on coumadin who require bridging	One week prior to procedure	Blostein	Vivianne Pananis #5982	<b>Roberta Tiscione #4793</b>
<b>PERIOP-2</b> <u>06-078</u>	RCT of placebo vs dalteparin for post-operative bridging	Patients on coumadin who require bridging	One week prior to procedure	Blostein	Vivianne Pananis #5982	<b>Roberta Tiscione #4793</b>
<b>SCHULMAN DABI STUDY</b> <u>12-037</u>	<b>Cohort study examining bridging for patients on dabigatran</b>	Patients on dabigatran requiring a surgical intervention	Within a week of a surgical intervention	Blostein	Viviane Pananis #5982	<b>Roberta Tiscione #4793</b>
<b>Warfarin Pharmacogenetic study</b> <u>09-1179</u>	Warfarin Pharmacogenetic study for patients on anticoagulation	Atrial Fibrillation newly diagnosed, men and women aged 18 years or older	Must be enrolled in a window up to 3 weeks after intervention of warfarin	Blostein	Viviane Pananis #5982	<b>Roberta Tiscione #4793</b>
<b>ITP STUDY</b>	Randomized Study comparing Eltrombopag vs IVIG y for patients with mild to moderate ITP who require a surgical intervention	Patients with mild to moderate ITP	4 weeks prior to surgery	Blostein	Viviane Pananis #5982	<b>Roberta Tiscione #4793</b>

### Active studies (follow-up phase; closed to recruitment)

Name of study/ Protocol number	Study Description	Site PI MD	Coordinator	Contact for Research Ethics Office
<b>ROAM</b> <u>11-016</u>	Resource utilization associated with warfarin management - Questionnaire	Blostein	Vivianne Pananis #5982	<b>Roberta Tiscione #4793</b>